Avalyn Pharma (NASDAQ:AVLN) Releases Quarterly Earnings Results, Beats Expectations By $0.05 EPS

Avalyn Pharma (NASDAQ:AVLN) announced its earnings results on Wednesday. The company reported ($0.98) EPS for the quarter, topping analysts’ consensus estimates of ($1.03) by $0.05, FiscalAI reports.

Avalyn Pharma Stock Performance

Shares of AVLN traded up $3.36 during mid-day trading on Wednesday, reaching $38.82. 172,400 shares of the company’s stock traded hands, compared to its average volume of 348,595. The stock has a market capitalization of $1.72 billion and a PE ratio of -1.78. The firm’s 50-day moving average is $29.49. Avalyn Pharma has a 12 month low of $24.15 and a 12 month high of $39.99.

Wall Street Analyst Weigh In

Several research firms recently weighed in on AVLN. Wall Street Zen upgraded Avalyn Pharma to a “hold” rating in a report on Saturday, May 9th. Guggenheim started coverage on shares of Avalyn Pharma in a research note on Monday, May 25th. They set a “buy” rating and a $80.00 price objective for the company. Morgan Stanley assumed coverage on shares of Avalyn Pharma in a research report on Tuesday, May 26th. They set an “overweight” rating and a $53.00 price objective on the stock. Evercore began coverage on shares of Avalyn Pharma in a research report on Tuesday, May 26th. They set an “outperform” rating and a $51.00 price objective on the stock. Finally, Jefferies Financial Group initiated coverage on shares of Avalyn Pharma in a research note on Monday, May 25th. They issued a “buy” rating and a $52.00 target price on the stock. Two analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $59.00.

Institutional Investors Weigh In On Avalyn Pharma

An institutional investor recently bought a new stake in Avalyn Pharma stock. Bank of New York Mellon Corp acquired a new stake in shares of Avalyn Pharma Inc. (NASDAQ:AVLN) in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 40,140 shares of the company’s stock, valued at approximately $1,321,000. Bank of New York Mellon Corp owned 0.09% of Avalyn Pharma as of its most recent SEC filing.

About Avalyn Pharma

We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.